市場調查報告書

B細胞非何傑金氏淋巴瘤(NHL) - 市場見解、流行病學、市場預測 ∼2028年

B-cell Non-Hodgkin's Lymphoma - Market Insights, Epidemiology, and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 923098
出版日期 內容資訊 英文 287 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
B細胞非何傑金氏淋巴瘤(NHL) - 市場見解、流行病學、市場預測 ∼2028年 B-cell Non-Hodgkin's Lymphoma - Market Insights, Epidemiology, and Market Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 287 Pages
簡介

非何傑金氏淋巴瘤(NHL)是發生在稱為淋巴球的白血球(WBC)的一種血液癌症,它也被稱為非何傑金氏病。一般而言,非何傑金氏淋巴瘤(NHL)發生於體內的一個或多個淋巴結中,可能透過淋巴系統從一組淋巴結轉移到另一組淋巴結。其並可能轉移到其他淋巴組織,特別是骨髓、脾臟,甚至是肝臟淋巴結。此外,它可能於發生在任何年齡,通常伴隨著淋巴結腫大、發燒、盜汗、體重減輕等症狀。非何傑金氏淋巴瘤(NHL)有許多類型,分為重度、中度、和緩性。主要7國(美國、英國、德國、法國、義大利、西班牙、日本)的B細胞非何傑金氏淋巴瘤(NHL)2017年發病數為14萬1,873人,推估同年市場規模達41億300萬美元。

本報告研究主要7國(美國、英國、德國、法國、義大利、西班牙、日本)的B細胞非何傑金氏淋巴瘤(NHL)市場,彙整疾病概要、現行治療法、市售治療藥與新藥簡介、主要7國市場趨勢、流行病學預測、市場規模,提供按性別、年齡、Subtype的發病數推移和預測,以及未滿足需求、市場成長因素和阻礙等整體性情報。

目錄

第1章 重要見解

第2章 摘要整理

第3章 SWOT分析

第4章 病患分佈

  • B細胞非何傑金氏淋巴瘤第一線治療病患分佈(實績數據)
  • B細胞非何傑金氏淋巴瘤第一線治療病患分佈(預測數據)
  • 復發/難治性B細胞非何傑金氏淋巴瘤病患分佈(實績數據)
  • 復發/難治性B細胞非何傑金氏淋巴瘤病患分佈(預測數據)

第5章 市場概要

  • B細胞非何傑金氏淋巴瘤病患分佈(實績數據)
  • B細胞非何傑金氏淋巴瘤病患分佈(預測數據)

第6章 疾病背景與概要

  • B細胞非何傑金氏淋巴瘤類型
    • 瀰漫型大B細胞淋巴瘤(DLBCL)
    • 伯奇氏淋巴瘤(BL)
    • 被套細胞淋巴瘤(MCL)
    • 濾泡性淋巴瘤(FL)
    • 緣帶淋巴瘤(MZL)
    • 慢性淋巴球白血病(CLL)/小細胞淋巴球淋巴瘤(SLL)
  • 起源與病因
    • 遺傳病變
    • 微環境交互作用與BCR的作用
  • 非何傑金氏淋巴瘤風險因素
  • B細胞非何傑金氏淋巴瘤病期分類
    • 成人的非何傑金氏淋巴瘤病期分類
    • 兒童的非何傑金氏淋巴瘤病期分類
    • 慢性淋巴球淋巴瘤(CLL)病期分類
  • 非何傑金氏淋巴瘤5年存活率
  • 非何傑金氏淋巴瘤的診斷
    • B細胞非何傑金氏淋巴瘤的診斷演算法
    • 評估
    • 診斷B細胞淋巴瘤的試驗策略
    • 使用實驗室技術的重度B細胞淋巴瘤階層化
    • 診斷病理學/分子生物學(DLBCL)建議事項摘要:歐洲腫瘤醫學會(ESMO)

第7章 流行病學與病患人數

  • 主要研究結果
  • 假設與基本原理(主要7國)

第8章 主要7國流行病學情勢

第8章 流行病學情勢:主要7國

  • 主要7國的非何傑金氏淋巴瘤發病數
    • B細胞非何傑金氏淋巴瘤總發病數
    • B細胞非何傑金氏淋巴瘤發病數:按性別
    • B細胞非何傑金氏淋巴瘤:按年齡
    • B細胞非何傑金氏淋巴瘤:按Subtype
    • B細胞非何傑金氏淋巴瘤:按病期

第9章 美國的流行病學

  • B細胞非何傑金氏淋巴瘤總發病數
  • B細胞非何傑金氏淋巴瘤:按年齡
  • B細胞非何傑金氏淋巴瘤:按Subtype
  • B細胞非何傑金氏淋巴瘤:按病期

第10章 歐洲5國的流行病學

  • 德國
    • B細胞非何傑金氏淋巴瘤總發病數
    • B細胞非何傑金氏淋巴瘤:按年齡
    • B細胞非何傑金氏淋巴瘤:按Subtype
    • B細胞非何傑金氏淋巴瘤:按病期
  • 法國
  • 義大利
  • 西班牙
  • 英國

第11章 日本的流行病學

  • B細胞非何傑金氏淋巴瘤總發病數
  • B細胞非何傑金氏淋巴瘤:按年齡
  • B細胞非何傑金氏淋巴瘤:按Subtype
  • B細胞非何傑金氏淋巴瘤:按病期

第12章 當前治療:白血病及淋巴腫瘤協會(LLS)

  • 治療概要
    • 影響治療的因素
    • 國際預後指數(IPI)
    • 兒童、青少年、年輕成人的治療考慮事項
  • B細胞非何傑金氏淋巴瘤的治療:按Subtype
    • 瀰漫型大B細胞淋巴瘤(DLBCL)
    • 伯奇氏淋巴瘤(BL)
    • 被套細胞淋巴瘤(MCL)
    • 濾泡性淋巴瘤(FL)
    • 緣帶淋巴瘤(MZL)
    • 小細胞淋巴球淋巴瘤(SLL)/慢性淋巴球白血病(CLL)

第13章 未滿足需求

第14章 已上市產品

  • Brukinsa (Zanubrutinib):BeiGene
    • 產品說明
    • 監管里程碑
    • 其他開發活動
    • 重要臨床試驗
    • 進行中的臨床試驗
  • Polivy (Polatuzumab vedotin):Hoffmann-La Roche
  • Ongoing Current Pipeline Activity
  • Venetoclax (ABT199): AbbVie and Roche
  • Kymriah (tisagenlecleucel): Novartis
  • Copiktra (Duvelisib): Verastem
  • Keytruda (Pembrolizumab): Merck Sharp & Dohme
  • Yescarta (Axicabtagene ciloleucel; KTE-C19):Gilead Sciences
  • Aliqopa (Copanlisib; BAY 80-6946): Bayer
  • Calquence (Acalabrutinib): AstraZeneca
  • Imbruvica (Ibrutinib):Janssen/Pharmacyclics (AbbVie Company)
  • Zydelig (Idelalisib):Gilead Sciences
  • Gazyva (Obinutuzumab, GA-101):Genentech (Roche Group)
  • Revlimid (lenalidomide):Celgene Corporation
  • Velcade (bortezomib):Takeda & Janssen Pharmaceutical
  • Zevalin (ibritumomab tiuxetan):Spectrum Pharmaceuticals Torisel:Pfizer

第15章 新藥

  • Tafasitamab (MOR208; formerly XmAb 5574):MorphoSys AG
  • Lisocabtagene maraleucel (JCAR017):Bristol-Myers Squibb
  • Enzastaurin Hydrochloride (DB102):Denovo Biopharma
  • Avelumab (Bavencio):Pfizer/Merck
  • Umbralisib (TG-1202):TG Therapeutics

第16章 主要7國的B細胞非何傑金氏淋巴瘤市場分析

  • 主要研究結果
  • 總市場規模
  • 市場規模:按治療藥級別

第17章 主要7國市場展望

第18章 美國市場規模

  • 總市場規模
  • 市場規模:按治療階段

第19章 歐洲5國市場規模

  • 德國
    • 總市場規模
    • 市場規模:按治療階段
  • 法國
  • 義大利
  • 西班牙
  • 英國

第20章 日本市場規模

  • 總市場規模
  • 市場規模:按治療階段

第21章 市場進入與償付情勢

  • CAR-T細胞療法

第22章 市場成長因素

第23章 市場阻礙

第24章 附錄

  • 參考書目
  • 報告方法

第25章 免責聲明

第26章 DelveInsight服務內容

第27章 關於DelveInsight

目錄
Product Code: DIMI0805

DelveInsight's 'B-cell Non-Hodgkin's Lymphoma-Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of B-cell NHL in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

B-cell NHL-Disease Understanding and Treatment Algorithm

NHL is a type of blood cancer that initially started in the white blood cells (WBCs) called lymphocytes, it is also known as non-Hodgkin's disease. Commonly the NHL occurs from lymph node at one or more places in the body, which can progress through the lymphatic system from one group of lymph nodes to another. It can progress to other lymph tissue, particularly in the bone marrow and spleen, or to lymph nodes in the liver.

NHL represents a heterogeneous group of malignancies of different biology and prognosis. It can occur at any age and are often marked by enlarged lymph nodes, fever, night sweats, and weight loss. There are different types of, and these are divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can develop from either B-cells or T-cells. Lymphomas that occur after allogeneic bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas and are collectively known as post-transplant lymph proliferative disorders.

B-cells or B lymphocytes help to protect the body against bacteria and viruses by making proteins called antibodies. Most of the cases of NHL are B-cell NHL. The exact cause of NHL is unknown but the factors that can increase the risk of developing the conditions are weakening of immune system, continuous uptake of immunosuppressant medication, and previous exposure of common virus-like Epstein-Barr virus. The diagnosis of NHL is mainly done by carrying out a biopsy. If it is confirmed by biopsy then further it is tested by a blood test, chest X-ray, CT scan, MRI Scan, PET scan, and Lumbar puncture, etc.

On the basis of diagnosis the treatment is done which includes chemotherapy, radiation therapy, targeted therapy, immunotherapy such as monoclonal antibodies, immune checkpoint inhibitors, and CAR T cells, and stem cell transplantation/bone marrow transplantation.

B-cell NHL Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incidence of NHL, Total Incidence cases of B cell-NHL, Gender-specific Incidence of B-cell NHL, Age-specific Incidence of B-cell NHL, Subtype - Specific Incidence of B-cell NHL and Stage-Specific Incidence of B-cell NHL] scenario of B-cell NHL in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2028.

DelveInsight's analysts have assessed that the total prevalent population of B-cell NHL in the 7MM was 141,873 in 2017. In addition to this, there was a gender difference in the disease. It was seen that, the B-cell lymphoma cases occurs more frequently in male population as compared to female. In 2017, a more number of males were affected by the disease, i.e., 55% of the B-cell NHL cases in the 7MM, which is equivalent to 78,030 cases in comparison to the females.

B-cell NHL Drug Chapters

The treatment of B-cell NHL is mainly based on the subtype and stage of the disease, according to the subtype and stage of the disease, initial therapy and intensity of treatment taken into consideration. In general, the goal of treatment is to destroy as many lymphoma cells as possible and to induce complete remission. Treatment can also keep non-Hodgkin lymphoma (NHL) in check for many years, even though imaging or other studies show the remaining sites of disease. This situation may be referred to as a "partial remission."

For patients without symptoms and with indolent subtypes of B-cell NHL, the treatment may be the watch-and-wait approach, meaning treatment is deferred or delayed until signs of disease progression occur. Frequent and careful observation is required so that effective treatment can be started if the disease starts advancing. Some patients have a long-time slow-growing disease, while others have a condition that evolves (transforms) into a more aggressive type of B-cell NHL that requires immediate treatment.

In general, chemotherapy and radiation therapy are the two principal forms of treatment for B-cell NHL. Although radiation therapy is often neither the sole nor the principal curative therapy, it is an important additional treatment in some cases.

The current treatment approaches include Rituximab based mono and combination therapies, Monoclonal antibodies based regimen except Rituximab, Immune Checkpoint inhibitors, Immunomodulators, Proteasome inhibitors, Kinase inhibitors, CAR-T cell therapies, and Histone deacetylase (HDAC) inhibitors.

The following drugs are approved under abovementioned classes, Brukinsa (Zanubrutinib, a product of BeiGene), Polivy (Polatuzumab vedotin, a product of Hoffmann-La Roche), Venetoclax (ABT199, a product of AbbVie and Roche), Kymriah (tisagenlecleucel, a product of Novartis), Yescarta (Axicabtagene ciloleucel, a product of Gilead Sciences), Aliqopa (Copanlisib, a product of Bayer), Imbruvica (Ibrutinib, a product of Janssen/Pharmacyclics (AbbVie Company)), Zydelig (Idelalisib, a product of Gilead Sciences), Gazyva (Obinutuzumab, a product of Genentech, Roche Group), Zevalin (ibritumomab tiuxetan, a product of Spectrum Pharmaceuticals), Velcade (bortezomib, a product of Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical), Revlimid (lenalidomide, a product of Celgene Corporation) and others.

B-cell NHL Market Outlook

The market size of B-cell NHL in seven major markets (7MM) is estimated to be USD 4,103 million in 2017. The United States accounts for the highest market size of B-cell NHL in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while Spain had the lowest market size of B-cell NHL in 2017.

B-cell NHL Drugs Uptake

With the launch of emerging therapies like Lisocabtagene maraleucel (JCAR017, a product of Bristol-Myers Squibb), which is an anti-CD-19-directed CAR T-cell product administered intravenously in defined composition at a precise dose of CD8 and CD4 CAR T cells which induced durable responses in poor-prognosis patients with R/R aggressive NHL after at least two prior therapies, KTE-X19 (Gilead Sciences), Tafasitamab (MOR208, a product of MorphoSys AG), Tazemetostat (E7438, a product of Epizyme), Abexinostat (Xynomic Pharmaceuticals), Umbralisib (TG Therapeutics), Avelumab (Pfizer/Merck) and others, the market of B-cell NHL is anticipated to change during the forecast period (2019-2028).

Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by DelveInsight's analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of B-cell NHL will have better management practices.

According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019-2028], and with their anticipated launch, the market size of B-cell NHL will also experience significant growth.

B-cell NHL Report Insights

  • Total Incidence of NHL
  • Total Incidence cases of B cell-NHL
  • Gender-specific Incidence of B-cell NHL
  • Age-specific Incidence of B-cell NHL
  • Subtype - Specific Incidence of B-cell NHL
  • Stage-Specific Incidence of B-cell NHL
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

B-cell NHL Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

B-cell NHL Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving B-cell NHL market
  • Organize sales and marketing efforts by identifying the best opportunities for B-cell NHL market
  • To understand the future market competition in the B-cell NHL market.

Table of Contents

1. Key Insights

2. Executive Summary of B-cell NHL

3. SWOT Analysis for B-cell NHL

4. B-cell NHL: Patient Share of B-cell NHL at a Glance

  • 4.1. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2017
  • 4.2. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2028
  • 4.3. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2017
  • 4.4. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2028

5. B-cell NHLs: Market Overview at a Glance

  • 5.1. Total Market Share (%) Distribution of B-cell NHL in 2017
  • 5.2. Total Market Share (%) Distribution of B-cell NHL in 2028

6. B-cell Non-Hodgkin Lymphoma (NHL): Disease Background and Overview

  • 6.1. Types of B-cell NHL
    • 6.1.1. Diffuse large B-cell lymphoma (DLBCL)
    • 6.1.2. Burkitt Lymphoma (BL)
    • 6.1.3. Mantle Cell Lymphoma (MCL)
    • 6.1.4. Follicular Lymphoma (FL)
    • 6.1.5. Marginal Zone Lymphoma (MZL)
    • 6.1.6. Chronic Lymphocytic Leukemia (CLL) and Small-Cell Lymphocytic Lymphoma (SLL)
  • 6.2. Origin and Pathogenesis of B-cell NHL
    • 6.2.1. Genetic Lesions in the Pathogenesis of B-cell Lymphomas
    • 6.2.2. Microenvironmental Interactions in B-Cell Lymphomas and the Role of the BCR
  • 6.3. Risk Factors for NHL
  • 6.4. Staging for B-cell NHL
    • 6.4.1. Staging of NHL in Adults
    • 6.4.2. Staging of NHL in Children
    • 6.4.3. Staging Systems for Chronic Lymphocytic Lymphoma (CLL)
  • 6.5. Survival Rate for NHL (5-year)
  • 6.6. Diagnosis of NHL
    • 6.6.1. Diagnostic Algorithm for B-cell NHL
    • 6.6.2. Evaluation
    • 6.6.3. Testing Strategies to Diagnose B-cell Lymphomas
    • 6.6.4. Stratification of High-Grade B-cell Lymphomas Using Laboratory Techniques
    • 6.6.5. Summary of Recommendations for Diagnosis and pathology/molecular biology (DLBCL): European Society for Medical Oncology (ESMO)

7. Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM

8. Epidemiology Scenario: 7MM

  • 8.1. Total Incidence of NHL in the 7MM
    • 8.1.1. Total Incidence cases of B cell-NHL in the 7MM
    • 8.1.2. Gender-specific Incidence of B-cell NHL in the 7MM
    • 8.1.3. Age-specific Incidence of B-cell NHL in the 7MM
    • 8.1.4. Subtype - Specific Incidence of B-cell NHL in the 7MM
    • 8.1.5. Stage-Specific Incidence of B-cell NHL in the 7MM

9. United States Epidemiology

  • 9.1. Total Incidence cases of B cell-NHL in the United States
  • 9.2. Age-specific Incidence of B-cell NHL in the United States
  • 9.3. Subtype-Specific Incidence of B-cell NHL in the United States
  • 9.4. Stage-Specific Incidence of B-cell NHL in the United States

10. EU-5 Country-wise Epidemiology

  • 10.1. Germany Epidemiology
    • 10.1.1. Total Incidence cases of B cell-NHL in Germany
    • 10.1.2. Age-specific Incidence of B-cell NHL in Germany
    • 10.1.3. Subtype-Specific Incidence of B-cell NHL in Germany
    • 10.1.4. Stage-Specific Incidence of B-cell NHL in Germany
  • 10.2. France Epidemiology
    • 10.2.1. Total Incidence cases of B cell-NHL in France
    • 10.2.2. Age-specific Incidence of B-cell NHL in France
    • 10.2.3. Subtype-Specific Incidence of B-cell NHL in France
    • 10.2.4. Stage-Specific Incidence of B-cell NHL in France
  • 10.3. Italy Epidemiology
    • 10.3.1. Total Incidence cases of B cell-NHL in Italy
    • 10.3.2. Age-specific Incidence of B-cell NHL in Italy
    • 10.3.3. Subtype-Specific Incidence of B-cell NHL in Italy
    • 10.3.4. Stage-Specific Incidence of B-cell NHL in Italy
  • 10.4. Spain Epidemiology
    • 10.4.1. Total Incidence cases of B cell-NHL in Spain
    • 10.4.2. Age-specific Incidence of B-cell NHL in Spain
    • 10.4.3. Subtype-Specific Incidence of B-cell NHL in Spain
    • 10.4.4. Stage-Specific Incidence of B-cell NHL in Spain
  • 10.5. United Kingdom Epidemiology
    • 10.5.1. Total Incidence cases of B cell-NHL in the United Kingdom
    • 10.5.2. Age-specific Incidence of B-cell NHL in the United Kingdom
    • 10.5.3. Subtype-Specific Incidence of B-cell NHL in the United Kingdom
    • 10.5.4. Stage-Specific Incidence of B-cell NHL in the United Kingdom

11. Japan Epidemiology

  • 11.1. Total Incidence cases of B cell-NHL in Japan
  • 11.2. Age-specific Incidence of B-cell NHL in Japan
  • 11.3. Subtype-Specific Incidence of B-cell NHL in Japan
  • 11.4. Stage-Specific Incidence of B-cell NHL in Japan

12. Current Treatment Practices for B-cell NHL: As per Leukemia & Lymphoma Society (LLS)

  • 12.1. Treatment Overview
    • 12.1.1. Factors That Influence Treatment
    • 12.1.2. The International Prognostic Index (IPI)
    • 12.1.3. Treatment Considerations for Children, Adolescents, and Young Adults
  • 12.2. Treatment of B-cell NHL Subtypes
    • 12.2.1. Diffuse Large B-Cell Lymphoma (DLBCL)
    • 12.2.2. Burkitt Lymphoma
    • 12.2.3. Mantle Cell Lymphoma (MCL)
    • 12.2.4. Follicular Lymphoma (FL)
    • 12.2.5. Marginal Zone Lymphoma (MZL)
    • 12.2.6. Small-Cell Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukemia (CLL)

13. Unmet Needs

14. Marketed Products

  • 14.1. Brukinsa (Zanubrutinib): BeiGene
    • 14.1.1. Product Description
    • 14.1.2. Regulatory Milestones
    • 14.1.3. Other Developmental Activities
    • 14.1.4. Pivotal Clinical Trials
    • 14.1.5. Ongoing Clinical Trials
  • 14.2. Polivy (Polatuzumab vedotin): Hoffmann-La Roche
    • 14.2.1. Product Description
    • 14.2.2. Regulatory Milestones
    • 14.2.3. Other Developmental Activities
    • 14.2.4. Pivotal Clinical Trials
    • 14.2.5. Ongoing Current Pipeline Activity
  • 14.3. Venetoclax (ABT199): AbbVie and Roche
    • 14.3.1. Product Description
    • 14.3.2. Regulatory Milestones
    • 14.3.3. Other Developmental Activities
    • 14.3.4. Pivotal Clinical Trials
    • 14.3.5. Ongoing Clinical Trials
  • 14.4. Kymriah (tisagenlecleucel): Novartis
    • 14.4.1. Product Description
    • 14.4.2. Regulatory Milestones
    • 14.4.3. Other Developmental Activities
    • 14.4.4. Pivotal Clinical Trials
    • 14.4.5. Ongoing Current Pipeline Activity
  • 14.5. Copiktra (Duvelisib): Verastem
    • 14.5.1. Product Description
    • 14.5.2. Regulatory Milestones
    • 14.5.3. Other Developmental Activities
    • 14.5.4. Pivotal Clinical Trials
  • 14.6. Keytruda (Pembrolizumab): Merck Sharp & Dohme
    • 14.6.1. Product Description
    • 14.6.2. Regulatory Milestones
    • 14.6.3. Pivotal Clinical Trials
    • 14.6.4. Ongoing Current Pipeline Activity
  • 14.7. Yescarta (Axicabtagene ciloleucel; KTE-C19): Gilead Sciences
    • 14.7.1. Product Description
    • 14.7.2. Regulatory Milestones
    • 14.7.3. Other Developmental Activities
    • 14.7.4. Pivotal Clinical Trials
    • 14.7.5. Ongoing Current Pipeline Activity
  • 14.8. Aliqopa (Copanlisib; BAY 80-6946): Bayer
    • 14.8.1. Product Description
    • 14.8.2. Regulatory Milestones
    • 14.8.3. Other Developmental Activities
    • 14.8.4. Pivotal Clinical Trials
    • 14.8.5. Ongoing Current Pipeline Activity
  • 14.9. Calquence (Acalabrutinib): AstraZeneca
    • 14.9.1. Product Description
    • 14.9.2. Regulatory Milestones
    • 14.9.3. Other Dvelopmental Activities
    • 14.9.4. Pivotal Clinical Trials
    • 14.9.5. Ongoing Clinical Trials
  • 14.10. Imbruvica (Ibrutinib): Janssen/Pharmacyclics (AbbVie Company)
    • 14.10.1. Product Description
    • 14.10.2. Regulatory Milestones
    • 14.10.3. Other Developmental Activities
    • 14.10.4. Pivotal Clinical Trials
    • 14.10.5. Ongoing Current Pipeline Activity
  • 14.11. Zydelig (Idelalisib): Gilead Sciences
    • 14.11.1. Product Description
    • 14.11.2. Regulatory Milestones
    • 14.11.3. Other Developmental Activities
    • 14.11.4. Pivotal Clinical Trials
    • 14.11.5. Ongoing Current Pipeline Activity
  • 14.12. Gazyva (Obinutuzumab, GA-101): Genentech (Roche Group)
    • 14.12.1. Product Description
    • 14.12.2. Regulatory Milestones
    • 14.12.3. Other Developmental Activities
    • 14.12.4. Pivotal Clinical Trials
    • 14.12.5. Ongoing Current Pipeline Activity
  • 14.13. Revlimid (lenalidomide): Celgene Corporation
    • 14.13.1. Product Description
    • 14.13.2. Regulatory Milestones
    • 14.13.3. Other Developmental Activities
    • 14.13.4. Pivotal Clinical Trials
    • 14.13.5. Ongoing Clinical Trials
  • 14.14. Velcade (bortezomib): Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical
    • 14.14.1. Product Description
    • 14.14.2. Regulatory Milestones
    • 14.14.3. Other Developmental Activities
    • 14.14.4. Pivotal Clinical Trials
    • 14.14.5. Ongoing Current Pipeline Activity
  • 14.15. Zevalin (ibritumomab tiuxetan): Spectrum Pharmaceuticals
    • 14.15.1. Product Description
    • 14.15.2. Regulatory Milestones
    • 14.15.3. Other Developmental Activities
    • 14.15.4. Pivotal Clinical Trials
  • 14.16. Torisel: Pfizer
    • 14.16.1. Product Description
    • 14.16.2. Regulatory Milestones
    • 14.16.3. Pivotal Clinical Trials

15. Emerging Therapies

  • 15.1. Key Cross
  • 15.2. Tafasitamab (MOR208; formerly XmAb 5574): MorphoSys AG
    • 15.2.1. Product Description
    • 15.2.2. Other Developmental Activities
    • 15.2.3. Clinical Development
    • 15.2.4. Safety and Efficacy
  • 15.3. Lisocabtagene maraleucel (JCAR017): Bristol-Myers Squibb
    • 15.3.1. Product Description
    • 15.3.2. Other Developmental Activities
    • 15.3.3. Clinical Development
    • 15.3.4. Safety and Efficacy
  • 15.4. Enzastaurin Hydrochloride (DB102): Denovo Biopharma
    • 15.4.1. Product Description
    • 15.4.2. Other Developmental Activities
    • 15.4.3. Clinical Development
    • 15.4.4. Safety and Efficacy
  • 15.5. Avelumab (Bavencio): Pfizer/Merck
    • 15.5.1. Product Description
    • 15.5.2. Other Developmental Activities
    • 15.5.3. Clinical Development
  • 15.6. Umbralisib (TG-1202): TG Therapeutics
    • 15.6.1. Product Description
    • 15.6.2. Other Developmental Activities
    • 15.6.3. Clinical Development
    • 15.6.4. Safety and Efficacy

16. B-cell NHL: Seven Major Market Analysis

  • 16.1. Key Findings
  • 16.2. Total Market Size of B-cell NHL in the 7MM
  • 16.3. Market Size of B-cell NHL by Therapeutic Class in the 7MM

17. Market Outlook: 7MM

18. United States Market Size

  • 18.1. Total Market size of B-cell NHL in the United States
  • 18.2. Market Size of B-cell NHL by Line of Therapies in the US

19. EU-5 Market Size

  • 19.1. Germany Market Size
    • 19.1.1. Total Market size of B-cell NHL in Germany
    • 19.1.2. Market Size of B-cell NHL by Line of Therapies in Germany
  • 19.2. France Market Size
    • 19.2.1. Total Market size of B-cell NHL in France
    • 19.2.2. Market Size of B-cell NHL by Therapies in France
  • 19.3. Italy Market Size
    • 19.3.1. Total Market size of B-cell NHL in Italy
    • 19.3.2. Market Size of B-cell NHL by Line of Therapies in Italy
  • 19.4. Spain Market Size
    • 19.4.1. Total Market size of B-cell NHL in Spain
    • 19.4.2. Market Size of B-cell NHL by Line of Therapies in Spain
  • 19.5. United Kingdom Market Size
    • 19.5.1. Total Market size of B-cell NHL in the United Kingdom
    • 19.5.2. Market Size of B-cell NHL by Line of Therapies in the United Kingdom

20. Japan Market Size

  • 20.1. Total Market size of B-cell NHL in Japan
  • 20.2. Market Size of B-cell NHL by Therapies in Japan

21. Market Access and Reimbursement Scenario of B-cell NHL Therapies

  • 21.1. CAR-T cell Therapies

22. Market Drivers

23. Market Barriers

24. Appendix

  • 24.1. Bibliography
  • 24.2. Report Methodology

25. Disclaimer

26. DelveInsight Capabilities

27. About DelveInsight

List of Tables

Table 1 Summary of B-cell NHL Market, Epidemiology, and Key Events (2017-2028)

Table 2 Stage-wise Survival Rate of DLBCL

Table 3 Stage wise Survival Rate of FL

Table 4 Stage wise Survival Rate of MZL

Table 5 Genetic Lesions in Human B-cell Lymphomas

Table 6 Rai Staging System

Table 7 Binet Staging System

Table 8 Major Sources Used

Table 9 Total Incidence of NHL in the 7MM (2017-2028)

Table 10 Total Incidence cases of B cell-NHL in the 7MM (2017-2028)

Table 11 Gender-specific Incidence of B-cell NHL in the 7MM (2017-2028)

Table 12 Age-specific Incidence of B-cell NHL in the 7MM (2017-2028)

Table 13 Subtype - Specific Incidence of B-cell NHL in the 7MM (2017-2028)

Table 14 Stage-Specific Incidence of B-cell NHL in the 7MM (2017-2028)

Table 15 Total Incidence cases of B cell-NHL in the United States (2017-2028)

Table 16 Age-specific Incidence of B-cell NHL in the United States (2017-2028)

Table 17 Subtype - Specific Incidence of B-cell NHL in the United States (2017-2028)

Table 18 Stage-Specific Incidence of B-cell NHL in the United States (2017-2028)

Table 19 Total Incidence cases of B cell-NHL in Germany (2017-2028)

Table 20 Age-specific Incidence of B-cell NHL in Germany (2017-2028)

Table 21 Subtype - Specific Incidence of B-cell NHL in Germany (2017-2028)

Table 22 Stage-Specific Incidence of B-cell NHL in Germany (2017-2028)

Table 23 Total Incidence cases of B cell-NHL in France (2017-2028)

Table 24 Age-specific Incidence of B-cell NHL in France (2017-2028)

Table 25 Subtype - Specific Incidence of B-cell NHL in France (2017-2028)

Table 26 Stage-Specific Incidence of B-cell NHL in France (2017-2028)

Table 27 Total Incidence cases of B cell-NHL in Italy (2017-2028)

Table 28 Age-specific Incidence of B-cell NHL in Italy (2017-2028)

Table 29 Subtype - Specific Incidence of B-cell NHL in Italy (2017-2028)

Table 30 Stage-Specific Incidence of B-cell NHL in Italy (2017-2028)

Table 31 Total Incidence cases of B cell-NHL in Spain (2017-2028)

Table 32 Age-specific Incidence of B-cell NHL in Spain (2017-2028)

Table 33 Subtype - Specific Incidence of B-cell NHL in Spain (2017-2028)

Table 34 Stage-Specific Incidence of B-cell NHL in Spain (2017-2028)

Table 35 Total Incidence cases of B cell-NHL in the United Kingdom ( (2017-2028)

Table 36 Age-specific Incidence of B-cell NHL in the United Kingdom (2017-2028)

Table 37 Subtype - Specific Incidence of B-cell NHL in the United Kingdom (2017-2028)

Table 38 Stage-Specific Incidence of B-cell NHL in the United Kingdom (2017-2028)

Table 39 Total Incidence cases of B cell-NHL in Japan (2017-2028)

Table 40 Age-specific Incidence of B-cell NHL in Japan (2017-2028)

Table 41 Subtype - Specific Incidence of B-cell NHL in Japan (2017-2028)

Table 42 Stage-Specific Incidence of B-cell NHL in Japan (2017-2028)

Table 43 Polivy, Clinical Trial Description, 2019

Table 44 Keytruda, Clinical Trial Description, 2019

Table 45 Gazyva, Clinical Trial Description, 2019

Table 46 Yescarta, Clinical Trial Description, 2019

Table 47 Aliqopa, Clinical Trial Description, 2019

Table 48 Ibrutinib, Clinical Trial Description, 2019

Table 49 Imbruvica, Clinical Trial Description, 2019

Table 50 Imbruvica, Clinical Trial Description, 2019

Table 51 Imbruvica, Clinical Trial Description, 2019

Table 52 Zydelig, Clinical Trial Description, 2019

Table 53 Gazyva, Clinical Trial Description, 2019

Table 54 Gazyva, Clinical Trial Description, 2019

Table 55 Velcade, Clinical Trial Description, 2019

Table 56 Emerging Drugs Key cross Competition

Table 57 Tafasitamab, Clinical Trial Description, 2019

Table 58 JCAR017, Clinical Trial Description, 2019

Table 59 Enzastaurin Hydrochloride (DB102) , Clinical Trial Description, 2019

Table 60 Avelumab , Clinical Trial Description, 2019

Table 61 Umbralisib (TGR-1202), Clinical Trial Description, 2019

Table 62 7MM Market Size of B-cell NHL in USD Million (2017-2028)

Table 63 7MM Market Size of B-cell NHL By Class in USD Million (2017-2028)

Table 64 List of Few Marketed Products with their respective Therapeutic Classes

Table 65 US Market Size of B-cell NHL By Class in USD Million (2017-2028)

Table 66 US Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017-2028)

Table 67 US Market Size of B-cell NHL of Relapsed/ Refractory in USD Million (2017-2028)

Table 68 Germany Market Size of B-cell NHL By Class in USD Million (2017-2028)

Table 69 Germany Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017-2028)

Table 70 Germany Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017-2028)

Table 71 France Market Size of B-cell NHL By Class in USD Million (2017-2028)

Table 72 France Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017-2028)

Table 73 France Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017-2028)

Table 74 Italy Market Size of B-cell NHL By Class in USD Million (2017-2028)

Table 75 Italy Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017-2028)

Table 76 Italy Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017-2028)

Table 77 Spain Market Size of B-cell NHL By Class in USD Million (2017-2028)

Table 78 Spain Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017-2028)

Table 79 Spain Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017-2028)

Table 80 United Kingdom Market Size of B-cell NHL By Class in USD Million (2017-2028)

Table 81 United Kingdom Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017-2028)

Table 82 United Kingdom Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017-2028)

Table 83 Japan Market Size of B-cell NHL By Class in USD Million (2017-2028)

Table 84 Japan Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017-2028)

Table 85 Japan Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017-2028)

Table 86 HTA Assessment in the EU-5 Countries

List of Figures

Figure 1 B-cell NHL SWOT Analysis

Figure 2 B-cell Development

Figure 3 Germinal Center Reaction and Cellular Origin of Human B-cell Lymphomas

Figure 4 Location of Non-Hodgkin Lymphoma in the Body for Stage 1

Figure 5 Location of Non-Hodgkin Lymphoma in the Body for Stage 2

Figure 6 Location of Non-Hodgkin Lymphoma in the Body for Stage 3

Figure 7 Location of Non-Hodgkin Lymphoma in the Body for Stage 4

Figure 8 Survival Rate for NHL

Figure 9 NHL 5-Year Relative Survival by Stage at Diagnosis

Figure 10 Diagnostic Algorithm for Major B-cell Lymphomas

Figure 11 Additional Tests for NHL

Figure 12 Global Heat Map of NHL

Figure 13 Total Incidence of NHL in the 7MM (2017-2028)

Figure 14 Total Incidence cases of B cell-NHL in the 7MM (2017-2028)

Figure 15 Gender-specific Incidence of B-cell NHL in the 7MM (2017-2028)

Figure 16 Age-specific Incidence of B-cell NHL in the 7MM (2017-2028)

Figure 17 Subtype - Specific Incidence of B-cell NHL in the 7MM (2017-2028)

Figure 18 Stage-Specific Incidence of B-cell NHL in the 7MM (2017-2028)

Figure 19 Total Incidence cases of B cell-NHL in the United States (2017-2028)

Figure 20 Age-specific Incidence of B-cell NHL in the United States (2017-2028)

Figure 21 Subtype - Specific Incidence of B-cell NHL in the United States (2017-2028)

Figure 22 Stage-Specific Incidence of B-cell NHL in the United States (2017-2028)

Figure 23 Total Incidence cases of B cell-NHL in Germany (2017-2028)

Figure 24 Age-specific Incidence of B-cell NHL in Germany (2017-2028)

Figure 25 Subtype - Specific Incidence of B-cell NHL in Germany (2017-2028)

Figure 26 Stage-Specific Incidence of B-cell NHL in Germany (2017-2028)

Figure 27 Total Incidence cases of B cell-NHL in France (2017-2028)

Figure 28 Age-specific Incidence of B-cell NHL in France (2017-2028)

Figure 29 Subtype - Specific Incidence of B-cell NHL in France (2017-2028)

Figure 30 Stage-Specific Incidence of B-cell NHL in France (2017-2028)

Figure 31 Total Incidence cases of B cell-NHL in Italy (2017-2028)

Figure 32 Age-specific Incidence of B-cell NHL in Italy (2017-2028)

Figure 33 Subtype - Specific Incidence of B-cell NHL in Italy (2017-2028)

Figure 34 Stage-Specific Incidence of B-cell NHL in Italy (2017-2028)

Figure 35 Total Incidence cases of B cell-NHL in Spain (2017-2028)

Figure 36 Age-specific Incidence of B-cell NHL in Spain (2017-2028)

Figure 37 Subtype - Specific Incidence of B-cell NHL in Spain (2017-2028)

Figure 38 Stage-Specific Incidence of B-cell NHL in Spain (2017-2028)

Figure 39 Total Incidence cases of B cell-NHL in the United Kingdom (2017-2028)

Figure 40 Age-specific Incidence of B-cell NHL in the United Kingdom (2017-2028)

Figure 41 Subtype - Specific Incidence of B-cell NHL in the United Kingdom (2017-2028)

Figure 42 Stage-Specific Incidence of B-cell NHL in the United Kingdom (2017-2028)

Figure 43 Total Incidence cases of B cell-NHL in Japan (2017-2028)

Figure 44 Age-specific Incidence of B-cell NHL in Japan (2017-2028)

Figure 45 Subtype - Specific Incidence of B-cell NHL in Japan (2017-2028)

Figure 46 Stage-Specific Incidence of B-cell NHL in Japan (2017-2028)

Figure 47 First Line Therapy Algorithm for DLBCL (Spanish Lymphoma Group (GELTAMO) Guidelines)

Figure 48 Treatment Algorithm for Patients with CLL/SLL

Figure 49 Unmet Needs of B-cell NHL

Figure 50 Market Size of B-cell NHL in the 7MM Countries in USD Million (2017-2028)

Figure 51 Market Size of B-cell NHL by therapies in the 7MM, in USD Million (2017-2028)

Figure 52 Market Size of B-cell NHL in the US, USD Millions (2017-2028)

Figure 53 Market Size of B-cell NHL By First-line Of Therapy in the US, USD Millions (2017-2028)

Figure 54 B-cell NHL By Relapsed and Refractory Market Size in the US, USD Millions (2017-2028)

Figure 55 Market Size of B-cell NHL in Germany, USD Millions (2017-2028)

Figure 56 Market Size of B-cell NHL By First-line Of Therapy in Germany, USD Millions (2017-2028)

Figure 57 Market Size of B-cell NHL By Relapsed and Refractory in Germany, USD Millions (2017-2028)

Figure 58 Market Size of B-cell NHL in France, USD Millions (2017-2028)

Figure 59 Market Size of B-cell NHL by first line of therapy in France, USD Millions (2017-2028)

Figure 60 B-cell NHL by Relapsed and Refractory Market Size, in France, USD Millions (2017-2028)

Figure 61 Market Size of B-cell NHL in Italy, USD Millions (2017-2028)

Figure 62 Market Size of B-cell NHL by first line of therapy in Italy, USD Millions (2017-2028)

Figure 63 B-cell NHL by Relapsed and Refractory Market Size in Italy, USD Millions (2017-2028)

Figure 64 Market Size of B-cell NHL in Spain, USD Millions (2017-2028)

Figure 65 Market Size of B-cell NHL by First line of Therapy in Spain, USD Millions (2017-2028)

Figure 66 B-cell NHL by Relapsed and Refractory Market Size in Spain, USD Millions (2017-2028)

Figure 67 Market Size of B-cell NHL in the United Kingdom USD Millions (2017-2028)

Figure 68 Market Size of B-cell NHL By First Line of Therapy in the United Kingdom in USD Millions (2017-2028)

Figure 69 B-cell NHL by Relapsed and Refractory Market Size in the United Kingdom in USD Millions (2017-2028)

Figure 70 Market Size of B-cell NHL in Japan, USD Millions (2017-2028)

Figure 71 Market Size of B-cell NHL in Japan, USD Millions (2017-2028)

Figure 72 B-cell NHL by Relapsed and Refractory Market Size in Japan in USD Millions (2017-2028)

Figure 73 Market Drivers of B-cell NHL

Figure 74 Market Barriers of B-cell NHL

Back to Top